New Fibrillarin Antibody
Potent Nucleoli MarkerGiven the importance ofNucleus and Related Markers to all branches of cell/molecular biology, we are dedicated to having the best.We have just added a newFibrillarin Antibody.Images: Immunofluorescent analysis of (A) C6 rat glioma cells and (B) Human embryonic kidney cells stained with mouse mAb to fibrillarin, MO22169, dilution 1:1,000 in red, in both cases costained with chicken pAb to vimentin, CPCA-Vim, dilution 1:10,000 in green. The blue is DAPI staining of nuclear DNA.Nop1p/Fibrillarin was originally identified as a nucleolar protein of bakers yeast, Saccharomyces cerevisiae (accession P15646)....
Source: Neuromics - June 4, 2018 Category: Neuroscience Tags: Fibrillarin Antibody Nuclear Staining Nucleoli Source Type: news

New study points to a potential 'Achilles heel' in brain cancer
(Virginia Commonwealth University) Scientists at Virginia Commonwealth University believe they have uncovered an 'Achilles heel' of glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. Their study published this week in the Proceedings of the National Academy of Sciences details how a mechanism that protects glioma stem cells can potentially be exploited to develop new and more effective treatments for GBM. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas
(Massachusetts General Hospital) Using a novel imaging method, a Massachusetts General Hospital research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2018 Category: International Medicine & Public Health Source Type: news

Operating on brain gliomas by detecting the 'glow'
(St. Joseph's Hospital and Medical Center) Research by Barrow Neurological Institute physicians and University of Washington scientists on novel imaging technology for malignant brain tumors was published in the April issue of World Neurosurgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news

Persistence pays off in discovery that could lead to improved treatment and survivability of patient
(Huntsman Cancer Institute) Gliomas are the most common type of central nervous system cancer but how these tumors develop is not fully understood. Sheri Holmen, PhD a researcher at Huntsman Cancer Institute (HCI) and professor of surgery at the University of Utah just published the results of her research on gliomas in Cell Reports. The work is focused on a mutated gene that is a critical piece of the puzzle for glioma development, according to Holmen's work. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

Glioma subtypes determine how the dangerous tumors spread, evade anti-angiogenic treatment
(Massachusetts General Hospital) A multi-institutional research team led by investigators at Massachusetts General Hospital and the University of California San Francisco has identified a new mechanism by which the dangerous brain tumors called gliomas develop resistance to anti-angiogenic treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2018 Category: Cancer & Oncology Source Type: news

Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 and Toca FC in the Greater China Region
Tocagen eligible to receive up to $127 million in upfront payment, development and commercial milestones, plus additional double-digit tiered sales royalties Upfront and near-term development milestones payments total up to $20 million SAN DIEGO and ... Biopharmaceuticals, Oncology, Licensing Tocagen, ApolloBio, immunotherapy, high grade glioma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 19, 2018 Category: Pharmaceuticals Source Type: news

The cellular composition of H3K27M gliomas
(Source: ScienceNOW)
Source: ScienceNOW - April 19, 2018 Category: Science Authors: Zahn, L. M. Tags: Genetics, Medicine, Diseases twis Source Type: news

Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq
Gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-glioma) arise primarily in the midline of the central nervous system of young children, suggesting a cooperation between genetics and cellular context in tumorigenesis. Although the genetics of H3K27M-glioma are well characterized, their cellular architecture remains uncharted. We performed single-cell RNA sequencing in 3321 cells from six primary H3K27M-glioma and matched models. We found that H3K27M-glioma primarily contain cells that resemble oligodendrocyte precursor cells (OPC-like), whereas more differentiated malignant cells are a minority. OPC-like ce...
Source: ScienceNOW - April 19, 2018 Category: Science Authors: Filbin, M. G., Tirosh, I., Hovestadt, V., Shaw, M. L., Escalante, L. E., Mathewson, N. D., Neftel, C., Frank, N., Pelton, K., Hebert, C. M., Haberler, C., Yizhak, K., Gojo, J., Egervari, K., Mount, C., van Galen, P., Bonal, D. M., Nguyen, Q.-D., Beck, A., Tags: Genetics, Medicine, Diseases reports Source Type: news

Biomarkers may help predict brain tumor recurrence, study says
Specific biomarkers have been identified that could help assess the likelihood and severity of the recurrence of malignant glioma, a form of brain cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 11, 2018 Category: Consumer Health News Source Type: news

Newly discovered biomarkers could be key to predicting severity of brain tumor recurrence
(Henry Ford Health System) Researchers have identified predictive biomarkers that could help assess the level of risk for recurrence in patients with malignant glioma. The study, led by Henry Ford Health System, was published today in Cell Reports. In an analysis of 200 tumor samples, the authors identified a set of epigenetic biomarkers that can predict, at a patient's initial diagnosis, which tumors are likely to recur with a more aggressive tumor type. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news

Biomarker panel can guide treatment of brain cancer
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Brazilian researchers have identified seven biomarkers that could be used at the time of the primary diagnosis to show which glioma patients will tend to progress to a more aggressive form of the disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 10, 2018 Category: International Medicine & Public Health Source Type: news

AI Beats Pathologists in Predicting Survival in Brain Cancer AI Beats Pathologists in Predicting Survival in Brain Cancer
A novel approach using artificial intelligence (AI) performed better than human pathologists when predicting overall survival for patients with gliomas.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 21, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Machines See the Future for Patients Diagnosed with Brain Tumors
For patients diagnosed with glioma, a deadly form of brain tumor, the future can be very uncertain. While gliomas are often fatal within two years of diagnosis, some patients can survive for 10 years or more. Predicting the course of a patient's disease at diagnosis is critical in selecting the right therapy and in helping patients and their families to plan their lives. (Source: eHealth News EU)
Source: eHealth News EU - March 14, 2018 Category: Information Technology Tags: Featured Research Research and Development Source Type: news

Machines see the future for patients diagnosed with brain tumors
(Emory Health Sciences) Researchers at Emory and Northwestern Universities have developed artificial intelligence (AI) software that can predict the survival of patients diagnosed with glioma by examining data from tissue biopsies. The approach is more accurate than the predictions of doctors who undergo years of highly-specialized training for the same purpose. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2018 Category: International Medicine & Public Health Source Type: news

Response of High-Grade Gliomas to Checkpoint Inhibitors Response of High-Grade Gliomas to Checkpoint Inhibitors
How should MRI findings be used to assess response of high-grade gliomas to immunotherapy?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Scientists target glioma cancer stem cells, which could improve patient survival
(Dartmouth-Hitchcock Medical Center) Brain tumors are responsible for 25 percent of cancer-related deaths in children and young adults. Despite initial response to treatment, most aggressive brain tumors eventually recur and are ultimately incurable. Multiple studies suggest that cancer stem cells within these tumors resist therapy and are responsible for tumor recurrences. Researchers at Dartmouth's Norris Cotton Cancer Center have devised a strategy to treat these tumors by identifying a secretion-mediated pathway that's essential for maintaining glioma cancer stem cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2018 Category: International Medicine & Public Health Source Type: news

Girl, 3, with brain tumour struggles to feed herself
Edie Molyneux, from Tranmere, will likely die young because of the rare mass on her brain, known as a diffuse intrinsic pontine glioma. (Source: the Mail online | Health)
Source: the Mail online | Health - January 25, 2018 Category: Consumer Health News Source Type: news

Tailoring cancer treatments to individual patients
(University of Texas at Austin, Texas Advanced Computing Center) The Center for Computational Oncology developed computer models to predict how cancer will progress in a specific individual, based on tissue, cellular and subcellular protein signaling responses. The models can predict how brain tumors (gliomas) will grow with much greater accuracy than previous models. Recently, the group began a clinical study to predict how an individual's cancer will progress after one cycle of therapy, and to use that prediction to plan the course of treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 3, 2018 Category: International Medicine & Public Health Source Type: news

Variation Seen in Hospice Use for Malignant Glioma
Differences by race, sex, age, level of education, urban versus rural residence identified (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 28, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Internal Medicine, Neurology, Nursing, Oncology, Anesthesiology & amp; Pain, Journal, Source Type: news

Many brain tumor patients do not receive adequate end-of-life care
(Massachusetts General Hospital) While more than 60 percent of patients with the brain tumors called malignant gliomas enroll in hospice services, almost a quarter of them do so within a week of death, probably too late for patients and family members to benefit from hospice care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2017 Category: Cancer & Oncology Source Type: news

UCLA grant program funds interdisciplinary brain cancer research
When a neurosurgeon looks at a glioblastoma, an aggressive form of brain cancer, she sees a dark mass bullying its way through the brain. When an oncologist talks to a patient with glioblastoma, he tempers expectations, talking in months rather than years. When a molecular biologist thinks about glioblastoma, she thinks about the tumor ’s sweet tooth — the sugar it consumes to fuel its frenetic growth. And when you put all these people together — you get a plan to fight cancer.Armed with new research tools and a grant from the David Geffen School of Medicine ’s newSeed Grant Program, a team of UCLA ...
Source: UCLA Newsroom: Health Sciences - December 18, 2017 Category: Universities & Medical Training Source Type: news

Novel mechanism that protects from glioblastoma identified
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) A group of researchers at the Spanish National Cancer Research Centre (CNIO) have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression. Moreover, reconstitution of RanBP6 in a mouse xenograft model leads to reduction in tumor growth. Authors state that these findings might have " important clinical implications " . (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 18, 2017 Category: Biology Source Type: news

25% of high-grade glioma patients alive 3 years post trial
Patients with recurrent high-grade glioma were treated by the University of Minnesota Medical School. Median survival was 14.4 months, compared with the typical 8 months. (Source: the Mail online | Health)
Source: the Mail online | Health - November 7, 2017 Category: Consumer Health News Source Type: news

Onalespib could be an effective treatment for glioblastoma, preclinical studies show
This study showed that the targeted drug onalespib reduced the expression of cell-survival proteins such as AKT and endothelial growth factor receptor in glioma cell lines and glioma stem cells from patient tumors. This, in turn, reduced the survival, proliferation, invasion and migration of the cells. In animal models of glioblastoma the agent crossed the blood-brain barrier and showed effectiveness as a single agent and greater effectiveness in combination with temozolomide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2017 Category: International Medicine & Public Health Source Type: news

25% of high-grade glioma patients live 3 years after trail
Patients with recurrent high-grade glioma were treated by the University of Minnesota Medical School. Median survival was 14.4 months, compared with the typical 8 months. (Source: the Mail online | Health)
Source: the Mail online | Health - November 1, 2017 Category: Consumer Health News Source Type: news

Gene Therapy May Fight Brain Cancer's Return
FRIDAY, Oct. 27, 2017 -- A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 27, 2017 Category: General Medicine Source Type: news

An experimental model might shed new light on the development of brain cancer in children
(DZNE - German Center for Neurodegenerative Diseases) Researchers of the German Center for Neurodegenerative Diseases (DZNE) present in the journal Cancer Cell a novel laboratory model that replicates key hallmarks of pediatric high-grade glioma. Results might pave the way for a better understanding of processes, relevant for both cancer and neurodegeneration. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 27, 2017 Category: International Medicine & Public Health Source Type: news

Cancer trial led by University of Minnesota Medical School's Dr. Clark Chen shows promise
(University of Minnesota Medical School) New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 27, 2017 Category: Cancer & Oncology Source Type: news

Biology of childhood brain tumor subtypes offers clues to precision treatments
(Children's Hospital of Philadelphia) Researchers investigating pediatric low-grade gliomas (PLGG), the most common type of brain tumor in children, have discovered key biological differences in how mutated genes combine with other genes to drive this childhood cancer. By shedding light on subtle distinctions in tumor biology, these findings offer clues to designing more effective anticancer treatments to precisely target tumors in individual patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells
(University Hospitals Cleveland Medical Center) Study demonstrates, for the first time, that glioblastoma (GBM) is driven by two distinct subsets of cancer stem cells. Moreover, each subtype of glioma stem cells is driven by distinct transcriptional programs for growth and treatment resistance. The subsets also responded better to combination treatment in the mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 9, 2017 Category: Cancer & Oncology Source Type: news

Papers of note in Nature 549 (7673)
This week’s articles highlight the role of vitamin C in hematopoietic cells; a source of maternal inflammation that contributes to neurodevelopmental defects; the blocking of a niche factor that promotes the growth of gliomas; and a protein that influences DNA repair pathway choice. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 3, 2017 Category: Science Authors: VanHook, A. M. Tags: STKE Editors ' Choice Source Type: news

Brainlab wins FDA nod for Elements Spine, Cranial SRS radiosurgery planning software
Brainlab said today it won FDA clearance for its Elements Spine SRS and Elements Cranial SRS radiosurgery surgical planning software applications. The Munich, Germany-based company said that the Elements Cranial SRS is designed to allow physicians to create radiosurgery plans in less than 15 minutes, supporting plans for numerous cranial indications including arteriovenous malformations, pituitary adenoma, vestibular schwannoma, glioma, meningioma and large brain metastases. “We are highly impressed with the dosimetric results and the speed of plan optimization. We ran a few plan comparisons between our other plannin...
Source: Mass Device - September 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Radiosurgery Regulatory/Compliance Software / IT Brainlab Source Type: news

Stanford researchers halt brain cancer growth with absence of protein
Research at Stanford University suggests the growth of specific brain tumors -- high-grade gliomas -- can be stopped by cutting off access to a signaling molecule. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 21, 2017 Category: Consumer Health News Source Type: news

Researchers hit the brakes on lethal brain cancers in mice
(NIH/National Institute of Neurological Disorders and Stroke) New research conducted in mice provides evidence that highly lethal brain tumors, called high-grade gliomas, stop growing when deprived of a specific molecule naturally produced when brain cells fire. The experiments, led by a group of scientists from Stanford University, Palo Alto, California, suggest that targeting a protein called neuroligin-3 may prove beneficial in patients with these diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

New study shows that genomic profiling can help improve treatment of brain tumors in children
(Wiley) The largest genomic profiling study ever conducted into a type of brain tumor known as glioma in children has identified genetic alterations in 96% of cases. As reported in The Oncologist, this genetic information could help to identify the most effective treatments for specific cases of glioma, hopefully improving the prognosis for what is currently the leading cause of death for children with cancer in the US. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2017 Category: Cancer & Oncology Source Type: news

Zika virus may be useful in treating brain tumours
Conclusion This is an interesting piece of research that shows how knowledge in one field of medicine can sometimes be applied to another field with surprising results. But it's important to be realistic about the stage of research. This is very much a "proof of concept" study, and tests on cells, tissues and mice don't necessarily translate into a safe and effective treatment for humans. The study has several limitations, but the fact the treatment so far hasn't been tested on humans is the most important. For one thing, Zika virus doesn't naturally infect mice, so researchers had to use a specially engineered v...
Source: NHS News Feed - September 6, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

New connections: Pleiotrophin and glioma
The cytokine pleiotrophin promotes the invasion and vascularization of glioma. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - September 5, 2017 Category: Science Authors: Wong, W. Tags: STKE Editors ' Choice Source Type: news

Oncolytic virotherapy offers new approach in treating brain tumors
For Jennifer Amsley and daughter Xia Martinez of Maryland, an oncolytic virotherapy study at Children ’s of Alabama has strengthened their resolve to fight and their desire for a sense of normalcy. Xia, 14, has an aggressive glioma brain tumor and an MRI showed new growth. That’s when doctors in Maryland informed Xia and her family of a clinical trial conducted by Dr. Gregory Friedman, associat e professor of pediatrics at the University of Alabama at Birmingham (UAB) and Children’s, and scientist… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2017 Category: Biotechnology Authors: Content provided by Children ’s of Alabama Source Type: news

Childhood Brain Stem Glioma Treatment
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 31, 2017 Category: General Medicine Source Type: news

Nanotech derived from amniotic stem cells could help treat brain cancer
Creative Medical Technology Holdings (OTC:CELZ) touted its exosome technology today, reporting that it demonstrated an ability to regenerate healthy brain cells while selectively halting the growth of glioma brain cancer cells in a preclinical model. The company’s exosomes are vesicles harvested from amniotic stem cell technology, which it licensed from the University of California San Diego in an exclusive deal for the AmnioStem platform. Get the full story at our sister site, Drug Delivery Business News. The post Nanotech derived from amniotic stem cells could help treat brain cancer appeared first o...
Source: Mass Device - July 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Neurological Oncology Research & Development Stent Grafts Wall Street Beat creativemedicaltechnologyholdings University of California at San Diego Source Type: news

Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma
SAN DIEGO, July 24, 2017 -- (Healthcare Sales & Marketing Network) -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted Toca 511 (vocimagene amiretrorepvec... Biopharmaceuticals, Oncology, Regulatory Tocagen, Toca 511, glioma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2017 Category: Pharmaceuticals Source Type: news

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance
(University of Alabama at Birmingham) A collaborative team of neuro-oncology surgeon/scientists -- led by Ichiro Nakano, M.D., Ph.D., University of Alabama at Birmingham, and Maode Wang, M.D., Xi'an Jiaotong University, Xi'an, China -- has discovered a unique and previously unidentified molecular mechanism that maintains glioma stem cells, and they have tested it as a potential therapeutic target in glioblastoma, using a novel small molecule inhibitor they designed and synthesized (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 24, 2017 Category: Cancer & Oncology Source Type: news

Addy Sooter headed to Mexico for treatment for brain tumor
Addy Sooter, who lives in Rogers, Arkansas, was diagnosed with a diffuse intrinsic pontine glioma (DIPG) brain tumor in November 2016. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2017 Category: Consumer Health News Source Type: news

Girl headed to Mexico for at treatment for brain tumor
Addy Sooter, who lives in Rogers, Arkansas, was diagnosed with a diffuse intrinsic pontine glioma (DIPG) brain tumor in November 2016. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2017 Category: Consumer Health News Source Type: news

FDA Approves Fluorescing Agent for Glioma Surgery
The US Food and Drug Administration has approved the optical imaging agent aminolevulinic acid hydrochloride to enhance visualization of malignant tissue during surgery for gliomas. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Brain Tumors News Source Type: news

Concussion researcher nets $25M for CTE program
Noted concussion researcher Dr. Julian Bailes has been awarded new grant...Read more on AuntMinnie.comRelated Reading: SNMMI: FET-PET could have answers for brainstem glioma SNMMI: PET can detect which plaques are at risk of rupture SNMMI partners with NDSC on appropriate use criteria SNMMI offers appropriate use criteria for 2 cancers SNMMI to Trump: Rescind travel ban (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2017 Category: Radiology Source Type: news

SNMMI: FET-PET could have answers for brainstem glioma
DENVER - Researchers in Switzerland are setting their sights on fluoroethyl-tyrosine...Read more on AuntMinnie.comRelated Reading: PET identifies cell mutations in NSCLC patients Novel PET tracer aids recurrent prostate cancer patients PET/CT CAD finds common spinal metastases PiB-PET could open window on common meningiomas ASTRO: PET predicts outcomes in vulvar cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 12, 2017 Category: Radiology Source Type: news

Parents share video of their daughter's dying moments
Katie King, from California, died in June 2016 from Diffuse Intrinsic Pontic Glioma. Her mother Jaime has shared this video to make people understand the true horror of the hopeless disease. (Source: the Mail online | Health)
Source: the Mail online | Health - June 8, 2017 Category: Consumer Health News Source Type: news

FDA OKs Gleolan, First Fluorescing Agent for Glioma Surgery FDA OKs Gleolan, First Fluorescing Agent for Glioma Surgery
Gleolan oral solution (aminolevulinic acid hydrochloride) enhances the visualization of malignant tissue during glioma surgery.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news